Category Business

JELMYTO® Shows Impressive 86% Recurrence-Free Survival (RFS) at 24 Months Across Varied Patient Profiles: Insights from AUA 2024 Retrospective Analysis

UroGen Pharma Ltd. (Nasdaq: URGN) has unveiled significant findings from a sub-analysis within the largest real-world patient cohort evaluation of JELMYTO (mitomycin) for pyelocalyceal solution, presented at the American Urological Association Meeting 2024 in San Antonio, TX. This analysis focused…

Read MoreJELMYTO® Shows Impressive 86% Recurrence-Free Survival (RFS) at 24 Months Across Varied Patient Profiles: Insights from AUA 2024 Retrospective Analysis

CHMP Recommends Approval of Truqap and Faslodex in the EU for Advanced ER-Positive Breast Cancer Patients

AstraZeneca’s Truqap (capivasertib) combined with Faslodex (fulvestrant) has received a positive recommendation for approval in the European Union (EU) for treating adult patients with locally advanced or metastatic breast cancer that is estrogen receptor (ER)-positive and HER2-negative. This recommendation comes…

Read MoreCHMP Recommends Approval of Truqap and Faslodex in the EU for Advanced ER-Positive Breast Cancer Patients

Lilly’s Q1 2024 Financials: Boosts Full-Year Revenue Projection by $2B, Highlights Pipeline Momentum

Eli Lilly and Company (NYSE: LLY) unveiled its financial performance for the first quarter of 2024 today. David A. Ricks, Lilly’s chair and CEO, commented on the company’s robust year-over-year revenue growth, attributing it to strong sales of Mounjaro and…

Read MoreLilly’s Q1 2024 Financials: Boosts Full-Year Revenue Projection by $2B, Highlights Pipeline Momentum

Amgen Prepares to Present Marketing Authorization Application for Teprotumumab to the European Medicines Agency

Amgen (NASDAQ:AMGN) has announced its forthcoming submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for teprotumumab. Teprotumumab, a fully human monoclonal antibody and targeted inhibitor of the insulin-like growth factor-1 receptor (IGF-1R), is aimed at…

Read MoreAmgen Prepares to Present Marketing Authorization Application for Teprotumumab to the European Medicines Agency

ATS Presentation: Sanofi’s Innovations in Immune-Mediated Respiratory Therapies

The American Thoracic Society (ATS) International Conference, scheduled from May 17-22 in San Diego, will host the unveiling of twenty-five abstracts featuring both approved and investigational medicines from Sanofi. Among the highlights are presentations on Dupixent® (dupilumab), developed in collaboration…

Read MoreATS Presentation: Sanofi’s Innovations in Immune-Mediated Respiratory Therapies

CHMP Recommends Approval of Bristol Myers Squibb’s Opdivo® for First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma

Bristol Myers Squibb (NYSE: BMY) has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Opdivo® (nivolumab) combined with cisplatin and gemcitabine as the first-line treatment for…

Read MoreCHMP Recommends Approval of Bristol Myers Squibb’s Opdivo® for First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma

EU Approves Vaidya as Additional Therapy for Adults with PNH and Persistent Haemolytic Anaemia Despite Rovelizumab or Eculizumab Treatment

Voydeya (danicopan) Receives EU Approval as Supplemental Treatment for Adults with PNH and Residual Hemolytic Anemia Voydeya (danicopan) has gained approval in the European Union (EU) to be used alongside ravulizumab or eculizumab for managing adult patients with paroxysmal nocturnal…

Read MoreEU Approves Vaidya as Additional Therapy for Adults with PNH and Persistent Haemolytic Anaemia Despite Rovelizumab or Eculizumab Treatment